M&A Deal Summary

Collegium Pharmaceutical Acquires Assertio Therapeutics - NUCYNTA

On February 6, 2020, Collegium Pharmaceutical acquired life science company Assertio Therapeutics - NUCYNTA from Assertio for 375M USD

Acquisition Highlights
  • This is Collegium Pharmaceutical’s 1st transaction in the Life Science sector.
  • This is Collegium Pharmaceutical’s 3rd largest (disclosed) transaction.
  • This is Collegium Pharmaceutical’s 1st transaction in the United States.
  • This is Collegium Pharmaceutical’s 1st transaction in California.

M&A Deal Summary
Date 2020-02-06
Target Assertio Therapeutics - NUCYNTA
Sector Life Science
Buyer(s) Collegium Pharmaceutical
Sellers(s) Assertio
Deal Type Divestiture
Deal Value 375M USD

Target

Assertio Therapeutics - NUCYNTA

California, United States
Assertio Therapeutics, Inc. - NUCYNTA is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short-term (acute) pain in adults when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Collegium Pharmaceutical

Stoughton, Massachusetts, United States
Category Company
Founded 2002
Sector Life Science
Employees197
Revenue 567M USD (2023)
DESCRIPTION

Collegium Pharmaceutical offers specialty pharmaceutical services by developing and planning to commercialize next-generation, abuse-deterrent products for patients suffering from chronic pain. Collegium Pharmaceutical was founded in 2002 and is based in Stoughton, Massachusetts.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 3
Year (2020) 1 of 1
Size (of disclosed) 3 of 3
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-14 BioDelivery

Raleigh, North Carolina, United States

BioDelivery is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BioDelivery was formed in 1997 and is based in Raleigh, North Carolina.

Buy $604M

Seller(S) 1

SELLER

Assertio

Lake Forest, Illinois, United States
Category Company
Founded 1995
Sector Life Science
Employees53
Revenue 152M USD (2023)
DESCRIPTION

Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 3 of 3
State (California) 2 of 2
Country (United States) 3 of 3
Year (2020) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-13 Assertio Therapeutics - Gralise Business

Newark, California, United States

Assertio Therapeutics, Inc. - Gralise Business is a prescription medicine used to treat pain after shingles, or postherpetic neuralgia (PHN).

Sell $128M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-16 Zyla Life Sciences

Wayne, Pennsylvania, United States

Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. Zyla Life Sciences portfolio includes six products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only - CII. Zyla Life Sciences was founded in 2010 and is based in Wayne, Pennsylvania.

Buy -
Mergr

Product

Company

Legal